Highland Park, IL, United States of America

Kim Lickteig

USPTO Granted Patents = 3 


Average Co-Inventor Count = 4.5

ph-index = 1


Location History:

  • San Francisco, CA (US) (2011)
  • San Mateo, CA (US) (2011)
  • Highland Park, IL (US) (2012)

Company Filing History:


Years Active: 2011-2012

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovator Kim Lickteig: Advancing Therapeutic Targets through Cutting-Edge Research

Introduction

Kim Lickteig, an accomplished inventor based in Highland Park, IL, has made significant contributions to the field of biotechnology. With a total of three patents to her name, Kim is recognized for her innovative approaches to understanding and modulating critical biological pathways.

Latest Patents

Kim's most recent patents focus on identifying therapeutic targets that may benefit individuals with disorders tied to defective PTEN and other related pathways. Her first patent, titled "Marks as Modifiers of the PTEN Pathway and Methods of Use," unveils human MARK genes as crucial modulators of the PTEN pathway, offering new avenues for treatment. This invention presents methods for screening agents that can influence MARK activity, marking a potential breakthrough in therapeutic interventions.

The second patent, "MAPKs as Modifiers of the Rac, Axin, and Beta-Catenin Pathways and Methods of Use," highlights human MAPK genes as key modulators of the Rac, axin, and beta-catenin pathways. This work emphasizes their importance in disorders caused by dysfunctional Rac, axin, and beta-catenin functions, and provides concrete methods for identifying modulators that can impact MAPK activity.

Career Highlights

Kim Lickteig is currently associated with Exelixis, Inc., a leading biotechnology company focused on developing innovative cancer therapies. Her work at Exelixis has positioned her at the forefront of significant advancements in the research and development of targeted treatments.

Collaborations

Throughout her career, Kim has collaborated with notable colleagues, including Michael R Costa and Timothy S Heuer. These partnerships have enriched her research, fostering a collaborative environment that encourages innovative solutions in biomedicine.

Conclusion

Kim Lickteig’s pioneering work reflects her commitment to advancing biotechnology and improving therapeutic options for patients with complex disorders. With a clear focus on understanding the molecular intricacies of disease, she continues to pave the way for future innovations in the scientific community. Her contributions not only highlight her inventiveness but also exemplify the profound impact that dedicated inventors can have on healthcare and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…